BrainsWay Ltd., a global leader in the advanced noninvasive treatment of brain disorders, announced the closing of its previously announced underwritten public offering of 5,315,300 American Depositary Shares, upsized to include 693,300 ADSs sold pursuant to the underwriters’ exercise in full of their option to purchase additional ADSs, at a price to the public of $8.50 per ADS. Checkout PrimeXBT
Source: https://www.biospace.com/article/releases/brainsway-ltd-announces-closing-of-45-2-million-underwritten-public-offering-of-american-depositary-shares-including-full-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares/?s=93